[1] Article Title: The clinical and molecular landscape of congenital myasthenic syndromes in Austria: a nationwide study
	•	Line(s): 7–8
	•	Section: Title Page
	•	Quote(s): “The clinical and molecular landscape of congenital myasthenic syndromes in Austria: a nationwide study”

⸻

[2] Publication Year: 2023
	•	Line(s): 10
	•	Section: Journal Info
	•	Quote(s): “Journal of Neurology (2023) 270:909–916”

⸻

[3] Region: Europe
	•	Line(s): 13
	•	Section: Title, Affiliations
	•	Quote(s): “Austria: a nationwide study”

⸻

[4] Country: Austria
	•	Line(s): 13
	•	Section: Title
	•	Quote(s): “in Austria: a nationwide study”

⸻

[5] Coverage Area: National
	•	Line(s): 36
	•	Section: Abstract / Methods
	•	Quote(s): “We used a nationwide approach to collect Austrian patients…”

⸻

[6] Study Design: Retrospective cohort study
	•	Line(s): 129
	•	Section: Patients and Methods
	•	Quote(s): “This retrospective, nationwide cohort study included all patients with genetically confirmed CMS…”

⸻

[7] Study Population: Patients with genetically confirmed CMS
	•	Line(s): 129
	•	Section: Patients and Methods
	•	Quote(s): “…included all patients with genetically confirmed CMS…”

⸻

[8] Population Characteristics: onset usually <1 year; 92.3% of CHRNE subgroup independently walking
	•	Line(s): 157–160, 198–201
	•	Section: Results – Demographic and Clinical Characteristics
	•	Quote(s):
	•	“In our study cohort, females accounted for 64.3%.”
	•	“One half of the patients experienced first symptoms just after birth or during the first year of life (50%).”
	•	“12/13 patients (92.3%) in this subgroup were still able to walk independently…”

⸻

[9] Data Source Type: Clinical data and genetic data
	•	Line(s): 131–137
	•	Section: Patients and Methods – Data Collection
	•	Quote(s): “…demographic, clinical and genetic details…”

⸻

[10] Data Source Details: Case report forms from neuromuscular centers, re-analyzed genetic variants
	•	Line(s): 131–138
	•	Section: Patients and Methods – Data Collection
	•	Quote(s):
	•	“…complete a pseudonymized case report form including demographic, clinical and genetic details.”
	•	“All genetic variants were re-analyzed…”

⸻

[11] Study Timeline Type: Retrospective
	•	Line(s): 129
	•	Section: Patients and Methods
	•	Quote(s): “This retrospective, nationwide cohort study…”

⸻

[12] Number of Sites: Multi-center
	•	Line(s): 128–129
	•	Section: Patients and Methods
	•	Quote(s): “…treated in one of the Austrian pediatric or adult neuromuscular centers…”
	•	Note: Exact number of sites not reported.

⸻

[13] Study Start Year: January 1, 2000
	•	Line(s): 130
	•	Section: Patients and Methods
	•	Quote(s): “…between 01/01/2000 and 31/12/2021.”

⸻

[14] Study End Year: December 31, 2021
	•	Line(s): 130
	•	Section: Patients and Methods
	•	Quote(s): “…between 01/01/2000 and 31/12/2021.”

⸻

[15] Main Ethnicity: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[16] Ethnicity Details: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[17] Disease Studied: Congenital myasthenic syndromes (CMS)
	•	Line(s): 13
	•	Section: Title / Abstract
	•	Quote(s): “The clinical and molecular landscape of congenital myasthenic syndromes…”

⸻

[18] Diagnosis Method: Genetic confirmation (NGS or single gene testing); clinical features also evaluated
	•	Line(s): 129, 144–146
	•	Section: Methods / Results
	•	Quote(s):
	•	“…patients with genetically confirmed CMS…”
	•	“Genetic analysis leading to molecular diagnosis…”

⸻

[19] Diagnosis Criteria Details: ACMG classification; pathogenic or likely pathogenic variants
	•	Line(s): 133–134
	•	Section: Data Collection
	•	Quote(s): “…only pathogenic and likely pathogenic variants according to the standards of the American College of Medical Genetics and Genomics (ACMG)…”

⸻

[20] Disease Phase: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[21] Cohort Age Group: Mixed
	•	Line(s): 127, 159
	•	Section: Methods / Results
	•	Quote(s):
	•	“…included all patients… who were treated in one of the Austrian pediatric or adult neuromuscular centers…”
	•	“…prevalence in the pediatric population (< 19 years) was 10.5 per million…”

⸻

[22] Female % in Cohort: 64.3%
	•	Line(s): 157
	•	Section: Results – Demographic and Clinical Characteristics
	•	Quote(s): “…females accounted for 64.3%.”

⸻

[23] Consanguinity: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR